← Eichor
Condition: Masld Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Masld

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Li
Phase N/A · 2 location(s) · Fundació Institut de Recerca de l'Hospital de la Santa Creu · NCT07652892Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians
Phase N/A · 1 location(s) · Novo Nordisk A/S · NCT07682363Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
NA · 1 location(s) · Henry Ford Health System · NCT07646197Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
Phase N/A · 1 location(s) · Ningbo No. 1 Hospital · NCT06984510Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
NA · 1 location(s) · Phenomen Pharma · NCT07068191A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Phase 2 · 5 location(s) · Regeneron Pharmaceuticals · NCT07527910Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
NA · 1 location(s) · Uppsala University · NCT06701968Corazones Unidos Study
NA · 1 location(s) · University of Arizona · NCT07298213Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813508Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NA · 2 location(s) · Pichamol Jirapinyo, MD, MPH · NCT06138821Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD
Phase N/A · 1 location(s) · Fundacion de Investigacion Science and Education · NCT06495333OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
NA · 1 location(s) · Changi General Hospital · NCT06890169Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis
NA · 1 location(s) · Universidad San Sebastián · NCT07552727Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Phase 2 · 17 location(s) · Madrigal Pharmaceuticals, Inc. · NCT07335601A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV
Phase 2 · 10 location(s) · Naga P. Chalasani · NCT07143968Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Non
NA · 3 location(s) · State Key Laboratory of Subhealth Intervention Technology · NCT07083336Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
NA · 3 location(s) · E-Scopics · NCT06661655Time-restricted Feeding in MASLD
NA · 1 location(s) · Universität des Saarlandes · NCT07530809EVOO and Metabolic Liver Health in MASLD
NA · 1 location(s) · Azienda Ospedaliera Specializzata in Gastroenterologia Saver · NCT07412444Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07440511Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
Phase N/A · 1 location(s) · Richmond Research Institute · NCT04873258SMART Diets for MASLD
Phase 2 · 1 location(s) · Michigan State University · NCT07459504Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComes
NA · 4 location(s) · Hospices Civils de Lyon · NCT06567990Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
NA · 1 location(s) · Taipei Medical University · NCT07692438A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07683065Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD
NA · 1 location(s) · Hospices Civils de Lyon · NCT07313007The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient
NA · 3 location(s) · University of Nottingham · NCT07093346Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
NA · 1 location(s) · Valbiotis · NCT06704321Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
NA · 2 location(s) · Cliniques universitaires Saint-Luc- Université Catholique de · NCT06506513Metabolic Features Effects on FAST Score in MASLD Patients
Phase N/A · 1 location(s) · Tanta University · NCT06867419
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.